Développement d’une approche vaccinale contre le cancer du poumon fondée sur un nouvel antigène tumoral

Développement d’une approche vaccinale contre le cancer du poumon fondée sur un nouvel antigène tumoral

Les thérapies anticancéreuses nécessitent aujourd’hui une approche plus ciblée. L’approche immunologique est devenue dans cette optique un enjeu d’importance notamment grâce à sa capacité d’atteindre de manière plus spécifique des cibles tumorales. Récemment, mon équipe a identifié des peptides anti...

Full description

Bibliographic Details
Main Author:	Virk, Yasemin
Other Authors:	Université Paris-Saclay (ComUE)
Language:	en
Published:	2016
Subjects:	Thérapies anticancéreuses La préprocalcitonine (ppCT) Anti-PD- 1 Cancer therapies PpCT Anti-PD-1
Online Access:	http://www.theses.fr/2016SACLS164

Similar Items

Parenting in Urban Slum Areas : Families with Children in a Shantytown of Rio de Janeiro
by: Kejerfors, Johan
Published: (2007)

A bioecological content analysis: An analysis technique rooted in the bioecological model for human development
by: Johanna Lundqvist, et al.
Published: (2019-12-01)

<sup>18</sup>F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
by: Giulia Polverari, et al.
Published: (2020-05-01)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
by: Paolo A. Ascierto, et al.
Published: (2017-08-01)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
by: Chunmeng Wang, et al.
Published: (2021-07-01)

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances
by: Semir Vranic
Published: (2017-08-01)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
by: Lydia Warburton, et al.
Published: (2020-11-01)

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
by: Jack M. Qian, et al.
Published: (2021-02-01)

p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses
by: Lei Miao, et al.
Published: (2020-01-01)

The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
by: Li Y, et al.
Published: (2021-02-01)

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
by: Martin Rao, et al.
Published: (2017-03-01)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
by: Xuanyi Wang, et al.
Published: (2020-04-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
by: Xiao-Dong Zhu, et al.
Published: (2021-03-01)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
by: Alessandro A. E. Testori, et al.
Published: (2020-07-01)

Overcoming Immune Evasion in Melanoma
by: Kevinn Eddy, et al.
Published: (2020-11-01)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
by: Xiangfeng Shen, et al.
Published: (2019-06-01)

Mothers' experiences of their child's diagnosis with an autism spectrum disorder / Melinda Wiese
by: Wiese, Melinda
Published: (2016)

Mothers' experiences of their child's diagnosis with an autism spectrum disorder / Melinda Wiese
by: Wiese, Melinda
Published: (2016)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
by: Robin Park, et al.
Published: (2020-03-01)

TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
by: Renpei Kato, et al.
Published: (2021-01-01)

The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study
by: Jin W, et al.
Published: (2020-11-01)

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
by: Kazumasa Oya, et al.
Published: (2021-08-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
by: Yuxiao Song, et al.
Published: (2020-08-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Current advances in kidney cancer immunotherapy
by: A. A. Korotaeva, et al.
Published: (2020-01-01)

Current Perspectives in Cancer Immunotherapy
by: Theodoulakis Christofi, et al.
Published: (2019-09-01)

Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy
by: Céline Dalmasso, et al.
Published: (2021-09-01)

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
by: Paolo A. Ascierto, et al.
Published: (2021-06-01)

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2019-07-01)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
by: Paolo A. Ascierto, et al.
Published: (2020-09-01)

The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018
by: Paolo A. Ascierto, et al.
Published: (2019-08-01)

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020
by: Paolo A. Ascierto, et al.
Published: (2021-04-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
by: Roman Groisberg, et al.
Published: (2017-12-01)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
by: Oliver Klein, et al.
Published: (2021-01-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
by: Michele Porcu, et al.
Published: (2019-03-01)